136 related articles for article (PubMed ID: 2249896)
21. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.
Mulé JJ; Schwarz SL; Roberts AB; Sporn MB; Rosenberg SA
Cancer Immunol Immunother; 1988; 26(2):95-100. PubMed ID: 2452015
[TBL] [Abstract][Full Text] [Related]
22. Allosensitization in IL-2-containing limiting dilution cultures generates cytotoxic T lymphocytes (CTL) rather than LAK cells reactive with a syngeneic nonimmunogenic murine tumor.
Leshem B; Epstein E; Kedar E
Immunol Lett; 1989 Jan; 20(1):53-8. PubMed ID: 2785493
[TBL] [Abstract][Full Text] [Related]
23. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Einstein AB; Fass L; Fefer A
Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization.
Leshem B; Kedar E
J Exp Med; 1990 Apr; 171(4):1057-71. PubMed ID: 2139097
[TBL] [Abstract][Full Text] [Related]
25. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulation and enhancement of antitumor activity by co-administration of 1,3-bis(2-chloroethyl)-1-nitrosourea and thymidine.
Poo WJ; Guo X; Haslund B; Mozdziesz DE
Biochem Pharmacol; 1997 Mar; 53(5):705-13. PubMed ID: 9113090
[TBL] [Abstract][Full Text] [Related]
27. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.
Parmiani G; Sensi ML; Carbone G; Colombo M; Pierotti M; Ballinari D; Hilgers J; Hilkens J
Int J Cancer; 1982 Mar; 29(3):323-32. PubMed ID: 7068280
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
Alderson MR; Sassenfeld HM; Widmer MB
J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
[TBL] [Abstract][Full Text] [Related]
29. High frequency of cross-reactive cytotoxic T lymphocytes elicited during the virus-induced polyclonal cytotoxic T lymphocyte response.
Nahill SR; Welsh RM
J Exp Med; 1993 Feb; 177(2):317-27. PubMed ID: 8093891
[TBL] [Abstract][Full Text] [Related]
30. Tumoricidal and immunomodulatory activities of drugs and implications for therapy of mice bearing a late stage MOPC-315 plasmacytoma.
Berko R; Seissman K; Colvin M; Bocian RC; Ben-Efraim S; Dray S
Int J Immunopharmacol; 1988; 10(7):825-34. PubMed ID: 3235239
[TBL] [Abstract][Full Text] [Related]
31. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
Baral E; Nagy E; Kangas L; Berczi I
Anticancer Res; 1997; 17(5A):3653-8. PubMed ID: 9413218
[TBL] [Abstract][Full Text] [Related]
32. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice.
Ehrke MJ; Verstovsek S; Maccubbin DL; Ujházy P; Zaleskis G; Berleth E; Mihich E
Int J Cancer; 2000 Jul; 87(1):101-9. PubMed ID: 10861459
[TBL] [Abstract][Full Text] [Related]
33. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
Suzuki R; Suzuki S; Ebina N; Kumagai K
J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
[TBL] [Abstract][Full Text] [Related]
34. Synergistic suppressive effect of double transfection of tumor necrosis factor-alpha and interleukin 12 genes on tumorigenicity of Meth-A cells.
Fujiwara H; Yamauchi N; Sato Y; Sasaki K; Takahashi M; Okamoto T; Sato T; Iyama S; Koshita Y; Hirayama M; Yamagishi H; Niitsu Y
Jpn J Cancer Res; 2000 Dec; 91(12):1296-302. PubMed ID: 11123429
[TBL] [Abstract][Full Text] [Related]
35. 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of spontaneous radiogenic C57BL mouse leukemia/lymphoma.
Maruyama Y; Feola JM; Muir W
Gan; 1983 Jun; 74(3):426-36. PubMed ID: 6309602
[TBL] [Abstract][Full Text] [Related]
36. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
37. Virus-induced polyclonal cytotoxic T lymphocyte stimulation.
Yang HY; Dundon PL; Nahill SR; Welsh RM
J Immunol; 1989 Mar; 142(5):1710-8. PubMed ID: 2537363
[TBL] [Abstract][Full Text] [Related]
38. Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma.
Grazioli L; Sensi M; Parmiani G
Cancer Immunol Immunother; 1987; 24(3):237-43. PubMed ID: 2954636
[TBL] [Abstract][Full Text] [Related]
39. Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.
Nagarkatti M; Clary SR; Nagarkatti PS
J Immunol; 1990 Jun; 144(12):4898-905. PubMed ID: 1972170
[TBL] [Abstract][Full Text] [Related]
40. Modulation of F1 cytotoxic potentials by GvHR. Host- and donor-derived cytotoxic lymphocytes arise in the unirradiated F1 host spleens under the condition of GvHR-associated immunosuppression.
Kubota E; Ishikawa H; Saito K
J Immunol; 1983 Sep; 131(3):1142-8. PubMed ID: 6604089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
